Latest Green Cross Health (NZX:GXH) News

Speculative small caps drove the week, with Tasman Resources, Solis Minerals and Lithium Energy leading the board after funding, drilling and asset sale updates. At the other end, ASX Ltd and Arafura Rare Earths fell hard as investors reacted to higher costs and fresh equity issuance.

Biotech names led healthcare trading this week, with Noxopharm, Acrux and TruScreen posting the biggest moves after clinical, licensing and expansion updates. Stronger cash flow, fresh capital and new contracts also lifted sentiment across medtech, aged care and healthcare services.

Green Cross Health lifted net profit by 28% to NZD 20.4 million in FY26, driven by stronger medical funding and pharmacy revenue growth, while preparing to launch a new Primary Health Organisation.

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.

Green Cross Health (NZX: GXH) has acknowledged discussions with third parties about a possible sale of its Medical division but emphasised that no transaction is guaranteed. The company remains committed to updating shareholders as the situation develops.